Clinical Trials Arena September 29, 2025
GlobalData

The acquisition enhances ACL Digital’s Life Sciences portfolio by incorporating specialised expertise in pharmacovigilance.

ACL Digital has acquired US-based contract research organisation (CRO) Symbiance to strengthen its position as a global end-to-end clinical research and data CRO solutions provider.

The acquisition also enhances ACL Digital’s life sciences portfolio by incorporating specialised expertise in pharmacovigilance, medical writing, biostatistics, data standardisation, clinical data management and statistical programming.

ACL Digital CEO Ramandeep Singh said: “The acquisition aligns with our growth strategy, enhancing our capabilities and delivering patient-centric, transformative solutions that exceed the standards of the life sciences industry.

“Together, we are positioned to accelerate innovation and drive operational efficiency for our clients. Moreover, ACL Digital’s AI-powered offerings, combined with Symbiance’s deep clinical research...

Today's Sponsors

Venturous
ZeOmega

Today's Sponsor

Venturous

Continue Reading

 
Topics: Clinical Trials, Mergers & Acquisitions / JV, Trends
Related Articles:
Worldwide Clinical Trials to Buy Catalyst, Another M&A Deal Between Private Equity-Backed CROs
Trial acceleration: AI supports progress, relationships drive success
Walmart Health Research Institute to Host Clinical Trials at 4 New Sites
Walmart To Launch Clinical Research Sites In Shuttered Health Clinics
2026: The time for AI to really deliver

Share Article